These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26310125)

  • 21. The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells.
    Cappellari M; Bielli P; Paronetto MP; Ciccosanti F; Fimia GM; Saarikettu J; Silvennoinen O; Sette C
    Oncogene; 2014 Jul; 33(29):3794-802. PubMed ID: 23995791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells.
    Rana M; Dong J; Robertson MJ; Basil P; Coarfa C; Weigel NL
    Sci Rep; 2021 Jan; 11(1):1393. PubMed ID: 33446905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
    Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP
    Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.
    Hu R; Dunn TA; Wei S; Isharwal S; Veltri RW; Humphreys E; Han M; Partin AW; Vessella RL; Isaacs WB; Bova GS; Luo J
    Cancer Res; 2009 Jan; 69(1):16-22. PubMed ID: 19117982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
    Magani F; Peacock SO; Rice MA; Martinez MJ; Greene AM; Magani PS; Lyles R; Weitz JR; Burnstein KL
    Mol Cancer Res; 2017 Nov; 15(11):1469-1480. PubMed ID: 28811363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
    Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
    J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.
    Shafi AA; Cox MB; Weigel NL
    Steroids; 2013 Jun; 78(6):548-54. PubMed ID: 23380368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.
    Nadiminty N; Tummala R; Liu C; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2015 Aug; 14(8):1884-95. PubMed ID: 26056150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x.
    Paronetto MP; Achsel T; Massiello A; Chalfant CE; Sette C
    J Cell Biol; 2007 Mar; 176(7):929-39. PubMed ID: 17371836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
    Peacock SO; Fahrenholtz CD; Burnstein KL
    Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upregulation of potential regulatory signaling molecules correlate with androgen receptor splice variants AR-V7 and AR-V567es in prostate cancer metastasis.
    Kiliccioglu I; Bilen CY; Sozen S; Konac E
    Gene; 2021 Mar; 772():145377. PubMed ID: 33359129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy.
    Pedrotti S; Bielli P; Paronetto MP; Ciccosanti F; Fimia GM; Stamm S; Manley JL; Sette C
    EMBO J; 2010 Apr; 29(7):1235-47. PubMed ID: 20186123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
    Chen Z; Wu D; Thomas-Ahner JM; Lu C; Zhao P; Zhang Q; Geraghty C; Yan PS; Hankey W; Sunkel B; Cheng X; Antonarakis ES; Wang QE; Liu Z; Huang TH; Jin VX; Clinton SK; Luo J; Huang J; Wang Q
    Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6810-6815. PubMed ID: 29844167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SAM68 promotes tumorigenesis in lung adenocarcinoma by regulating metabolic conversion via PKM alternative splicing.
    Zhu S; Chen W; Wang J; Qi L; Pan H; Feng Z; Tian D
    Theranostics; 2021; 11(7):3359-3375. PubMed ID: 33537092
    [No Abstract]   [Full Text] [Related]  

  • 36. Role of androgen receptor splice variants, their clinical relevance and treatment options.
    Wach S; Taubert H; Cronauer M
    World J Urol; 2020 Mar; 38(3):647-656. PubMed ID: 30659302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
    Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
    [No Abstract]   [Full Text] [Related]  

  • 38. Protein Sam68 regulates the alternative splicing of survivin DEx3.
    Gaytan-Cervantes J; Gonzalez-Torres C; Maldonado V; Zampedri C; Ceballos-Cancino G; Melendez-Zajgla J
    J Biol Chem; 2017 Aug; 292(33):13745-13757. PubMed ID: 28655776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
    Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
    Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1.
    Melnyk JE; Steri V; Nguyen HG; Hwang YC; Gordan JD; Hann B; Feng FY; Shokat KM
    Oncogene; 2022 Mar; 41(11):1536-1549. PubMed ID: 35087237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.